TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation
Brief Summary: The objective of this application is to identify a pharmacologic agent which helps couples in whom the female partner ovulates regularly successfully obtain their goal of delivering a healthy child, whose use will result in low rates of multiple gestations. The central hypothesis is that, in infertile ovulatory women undergoing ovarian stimulation (OS) and intrauterine insemination (IUI), the use of aromatase inhibitors (AI) will stimulate the ovaries sufficiently to produce no reduction in the rate of pregnancy, while significantly reducing the numbers of multiple gestational pregnancies that result from stimulation with clomiphene citrate (CC) or follicle stimulating hormone (FSH). The rationale for the proposed research is that reduction of multiple pregnancy rates could significantly reduce maternal and neonatal morbidity and mortality, as well as the cost of healthcare for these individuals and society.


Options:
A: Arm Label: Letrozole/IUI; Type: EXPERIMENTAL; Interventions: Drug: Letrozole/IUI | Arm Label: CC/IUI; Type: ACTIVE_COMPARATOR; Interventions: Drug: CC/IUI | Intervention Type: DRUG; Name: Letrozole/IUI; Assigned to Arm(s): Letrozole/IUI | Intervention Type: DRUG; Name: CC/IUI; Assigned to Arm(s): CC/IUI
B: Arm Label: Extended letrozole regimen; Type: EXPERIMENTAL; Interventions: Drug: Extended letrozole regimen | Arm Label: Clomiphene citrate regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clomiphene citrate regimen | Intervention Type: DRUG; Name: Extended letrozole regimen; Assigned to Arm(s): Extended letrozole regimen | Intervention Type: DRUG; Name: Clomiphene citrate regimen; Assigned to Arm(s): Clomiphene citrate regimen
C: Arm Label: "Individual" or "standard" rFSH dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: rFSH drug dose | Arm Label: "Standard" rFSH dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: "Standard" rFSH dose | Intervention Type: DRUG; Name: rFSH drug dose; Assigned to Arm(s): "Individual" or "standard" rFSH dose | Intervention Type: DRUG; Name: "Standard" rFSH dose; Assigned to Arm(s): "Standard" rFSH dose
D: Arm Label: Aromatase Inhibitors (AI); Type: ACTIVE_COMPARATOR; Interventions: Drug: Letrozole (aromatase inhibitor) | Arm Label: Clomiphene Citrate (CC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Clomiphene Citrate | Arm Label: Follicle Stimulating Hormone (FSH); Type: ACTIVE_COMPARATOR; Interventions: Drug: Follicle Stimulating Hormone (gonadotropin) | Intervention Type: DRUG; Name: Letrozole (aromatase inhibitor); Assigned to Arm(s): Aromatase Inhibitors (AI) | Intervention Type: DRUG; Name: Clomiphene Citrate; Assigned to Arm(s): Clomiphene Citrate (CC) | Intervention Type: DRUG; Name: Follicle Stimulating Hormone (gonadotropin); Assigned to Arm(s): Follicle Stimulating Hormone (FSH)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation
Brief Summary: The objective of this application is to identify a pharmacologic agent which helps couples in whom the female partner ovulates regularly successfully obtain their goal of delivering a healthy child, whose use will result in low rates of multiple gestations. The central hypothesis is that, in infertile ovulatory women undergoing ovarian stimulation (OS) and intrauterine insemination (IUI), the use of aromatase inhibitors (AI) will stimulate the ovaries sufficiently to produce no reduction in the rate of pregnancy, while significantly reducing the numbers of multiple gestational pregnancies that result from stimulation with clomiphene citrate (CC) or follicle stimulating hormone (FSH). The rationale for the proposed research is that reduction of multiple pregnancy rates could significantly reduce maternal and neonatal morbidity and mortality, as well as the cost of healthcare for these individuals and society.


Options:
A: Intervention Type: DRUG; Name: metformin XR; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: clomiphene citrate; Assigned to Arm(s): N/A
B: Arm Label: BMI > 32; Type: EXPERIMENTAL; Interventions: Drug: Metformin, Drug: Placebo | Arm Label: BMI </= 32; Type: EXPERIMENTAL; Interventions: Drug: Metformin + Clomiphene, Drug: Metformin, Drug: Clomiphene | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): BMI > 32 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BMI > 32 | Intervention Type: DRUG; Name: Metformin + Clomiphene; Assigned to Arm(s): BMI </= 32 | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): BMI </= 32 | Intervention Type: DRUG; Name: Clomiphene; Assigned to Arm(s): BMI </= 32
C: Arm Label: Aromatase Inhibitors (AI); Type: ACTIVE_COMPARATOR; Interventions: Drug: Letrozole (aromatase inhibitor) | Arm Label: Clomiphene Citrate (CC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Clomiphene Citrate | Arm Label: Follicle Stimulating Hormone (FSH); Type: ACTIVE_COMPARATOR; Interventions: Drug: Follicle Stimulating Hormone (gonadotropin) | Intervention Type: DRUG; Name: Letrozole (aromatase inhibitor); Assigned to Arm(s): Aromatase Inhibitors (AI) | Intervention Type: DRUG; Name: Clomiphene Citrate; Assigned to Arm(s): Clomiphene Citrate (CC) | Intervention Type: DRUG; Name: Follicle Stimulating Hormone (gonadotropin); Assigned to Arm(s): Follicle Stimulating Hormone (FSH)
D: Arm Label: metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin | Arm Label: liraglutide; Type: ACTIVE_COMPARATOR; Interventions: Drug: liraglutide | Arm Label: metformin and liraglutide; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin and liraglutide | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): metformin | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): liraglutide | Intervention Type: DRUG; Name: metformin and liraglutide; Assigned to Arm(s): metformin and liraglutide

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Brief Summary: The purpose of this study is to evaluate the efficacy, safety and tolerability of aclidinium bromide doses compared with placebo in the treatment of moderate to severe, stable chronic obstructive pulmonary disease. The study will be 56 weeks in duration; a 2-week run-in period followed by a 12-week double-blind, placebo-controlled treatment period. This will be followed by an open-label 40-week treatment period and a 2-week follow up phone call. All patients will receive the higher Aclidinium Bromide during the 40-week open label treatment period.


Options:
A: Arm Label: Olodaterol (BI1744) Low; Type: EXPERIMENTAL; Interventions: Drug: Olodaterol (BI 1744) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Olodaterol (BI 1744) High; Type: EXPERIMENTAL; Interventions: Drug: Olodaterol (BI 1744) | Intervention Type: DRUG; Name: Olodaterol (BI 1744); Assigned to Arm(s): Olodaterol (BI 1744) High | Intervention Type: DRUG; Name: Olodaterol (BI 1744); Assigned to Arm(s): Olodaterol (BI1744) Low | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
C: Intervention Type: DRUG; Name: Tiotropium bromide 18mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Fluticasone propionate/ salmeterol combination 50/500mcg; Assigned to Arm(s): N/A
D: Arm Label: Indacaterol 150 µg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 μg capsules | Arm Label: Indacaterol 300 µg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 300 μg capsules | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsules | Intervention Type: DRUG; Name: Indacaterol 150 μg capsules; Assigned to Arm(s): Indacaterol 150 µg | Intervention Type: DRUG; Name: Indacaterol 300 μg capsules; Assigned to Arm(s): Indacaterol 300 µg | Intervention Type: DRUG; Name: Placebo capsules; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Brief Summary: The purpose of this study is to evaluate the efficacy, safety and tolerability of aclidinium bromide doses compared with placebo in the treatment of moderate to severe, stable chronic obstructive pulmonary disease. The study will be 56 weeks in duration; a 2-week run-in period followed by a 12-week double-blind, placebo-controlled treatment period. This will be followed by an open-label 40-week treatment period and a 2-week follow up phone call. All patients will receive the higher Aclidinium Bromide during the 40-week open label treatment period.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
B: Arm Label: Aclidinium 400 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 400 μg bid | Arm Label: Tiotropium 18 μg once-daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium 18 μg once-daily | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide 400 μg bid; Assigned to Arm(s): Aclidinium 400 μg bid | Intervention Type: DRUG; Name: Tiotropium 18 μg once-daily; Assigned to Arm(s): Tiotropium 18 μg once-daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Aclidinium 200 μg once-daily; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): Aclidinium 200 μg once-daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of the National Taiwan University Hospital Elder Life Program
Brief Summary: The aim is to replicate, develop, and pilot test a model of care for the prevention and management of functional decline of older patients during hospitalization.


Options:
A: Arm Label: multifaceted prevention program; Type: EXPERIMENTAL; Interventions: Behavioral: Multifaceted prevention program HELP(Hospital Elder Life Program) | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Multifaceted prevention program HELP(Hospital Elder Life Program); Assigned to Arm(s): multifaceted prevention program
B: Arm Label: Cognitive Exercise; Type: EXPERIMENTAL; Interventions: Other: Mini-Mental State Examination, Other: Self-Administered Gerocognitive Examination, Other: Geriatric Depression Scale, Other: Charlson Comorbidity Index, Other: Short Form 36 Health Survey, Other: Confusion Assessment Method, Other: Memorial Delirium Assessment Scale, Other: Postoperative Quality of Recovery Scale | Arm Label: Normal Activity; Type: PLACEBO_COMPARATOR; Interventions: Other: Mini-Mental State Examination, Other: Self-Administered Gerocognitive Examination, Other: Geriatric Depression Scale, Other: Charlson Comorbidity Index, Other: Short Form 36 Health Survey, Other: Confusion Assessment Method, Other: Memorial Delirium Assessment Scale, Other: Postoperative Quality of Recovery Scale | Intervention Type: OTHER; Name: Mini-Mental State Examination; Assigned to Arm(s): Cognitive Exercise, Normal Activity | Intervention Type: OTHER; Name: Self-Administered Gerocognitive Examination; Assigned to Arm(s): Cognitive Exercise, Normal Activity | Intervention Type: OTHER; Name: Geriatric Depression Scale; Assigned to Arm(s): Cognitive Exercise, Normal Activity | Intervention Type: OTHER; Name: Charlson Comorbidity Index; Assigned to Arm(s): Cognitive Exercise, Normal Activity | Intervention Type: OTHER; Name: Short Form 36 Health Survey; Assigned to Arm(s): Cognitive Exercise, Normal Activity | Intervention Type: OTHER; Name: Confusion Assessment Method; Assigned to Arm(s): Cognitive Exercise, Normal Activity | Intervention Type: OTHER; Name: Memorial Delirium Assessment Scale; Assigned to Arm(s): Cognitive Exercise, Normal Activity | Intervention Type: OTHER; Name: Postoperative Quality of Recovery Scale; Assigned to Arm(s): Cognitive Exercise, Normal Activity
C: Arm Label: Usual Care Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Experimental Group; Type: EXPERIMENTAL; Interventions: Behavioral: a modified NTU-HELP | Intervention Type: BEHAVIORAL; Name: a modified NTU-HELP; Assigned to Arm(s): Experimental Group
D: Arm Label: Fam-FFC; Type: EXPERIMENTAL; Interventions: Behavioral: Family-centered Function-focused Care (Fam-FFC) | Arm Label: Attention Control (Fam- FFC Ed-only); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Family-centered Function-focused Care (Fam-FFC); Assigned to Arm(s): Fam-FFC

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of the National Taiwan University Hospital Elder Life Program
Brief Summary: The aim is to replicate, develop, and pilot test a model of care for the prevention and management of functional decline of older patients during hospitalization.


Options:
A: Arm Label: CPAP therapy arm; Type: EXPERIMENTAL; Interventions: Other: CPAP treatment | Arm Label: Control arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: CPAP treatment; Assigned to Arm(s): CPAP therapy arm
B: Arm Label: Usual Care Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Experimental Group; Type: EXPERIMENTAL; Interventions: Behavioral: a modified NTU-HELP | Intervention Type: BEHAVIORAL; Name: a modified NTU-HELP; Assigned to Arm(s): Experimental Group
C: Arm Label: Lumosity (CT Group); Type: EXPERIMENTAL; Interventions: Device: Lumosity | Arm Label: Usual Care (Control Group); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Lumosity; Assigned to Arm(s): Lumosity (CT Group)
D: Arm Label: Hydration: Normal Saline (salt water); Type: EXPERIMENTAL; Interventions: Drug: Saline | Arm Label: Placebo: Lower Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Hydration: Normal Saline (salt water) | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Placebo: Lower Saline

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: For Moms: Culturally Relevant Treatment Services for Perinatal Depression
Brief Summary: The study will evaluate the effectiveness of a culturally relevant, multi-component intervention for antenatal depression. The intervention includes an engagement session, and the woman's choice of brief interpersonal psychotherapy and/or pharmacotherapy in a stepped care treatment for depression model.


Options:
A: Arm Label: Self Empowerment Groups; Type: EXPERIMENTAL; Interventions: Behavioral: Self Empowerment Groups, Behavioral: Financial Empowerment, Behavioral: Matched Savings | Arm Label: Financial Empowerment; Type: EXPERIMENTAL; Interventions: Behavioral: Financial Empowerment, Behavioral: Matched Savings | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Self Empowerment Groups; Assigned to Arm(s): Self Empowerment Groups | Intervention Type: BEHAVIORAL; Name: Financial Empowerment; Assigned to Arm(s): Financial Empowerment, Self Empowerment Groups | Intervention Type: BEHAVIORAL; Name: Matched Savings; Assigned to Arm(s): Financial Empowerment, Self Empowerment Groups
B: Arm Label: TAU; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: TAU | Arm Label: DCM; Type: EXPERIMENTAL; Interventions: Behavioral: Care Management for Postpartum Depression | Intervention Type: BEHAVIORAL; Name: Care Management for Postpartum Depression; Assigned to Arm(s): DCM | Intervention Type: BEHAVIORAL; Name: TAU; Assigned to Arm(s): TAU
C: Arm Label: MOMCare intervention; Type: EXPERIMENTAL; Interventions: Behavioral: MOMCare | Arm Label: Care Plus; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: MOMCare; Assigned to Arm(s): MOMCare intervention
D: Arm Label: Immediate e-NET Group; Type: EXPERIMENTAL; Interventions: Behavioral: e-Net for Parents of Neurodiverse Children | Arm Label: Wait List Control Group; Type: EXPERIMENTAL; Interventions: Behavioral: e-Net for Parents of Neurodiverse Children | Intervention Type: BEHAVIORAL; Name: e-Net for Parents of Neurodiverse Children; Assigned to Arm(s): Immediate e-NET Group, Wait List Control Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: For Moms: Culturally Relevant Treatment Services for Perinatal Depression
Brief Summary: The study will evaluate the effectiveness of a culturally relevant, multi-component intervention for antenatal depression. The intervention includes an engagement session, and the woman's choice of brief interpersonal psychotherapy and/or pharmacotherapy in a stepped care treatment for depression model.


Options:
A: Arm Label: Intervention Patients & Providers; Type: EXPERIMENTAL; Interventions: Behavioral: DECIDE-PA | Arm Label: Intervention Patients, Control Providers; Type: EXPERIMENTAL; Interventions: Behavioral: DECIDE-PA | Arm Label: Control Patients, Intervention Providers; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Control Patients & Providers; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Non-Randomized Controlled Trial Patients; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Control Providers; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Providers; Type: EXPERIMENTAL; Interventions: Behavioral: DECIDE-PC | Intervention Type: BEHAVIORAL; Name: DECIDE-PA; Assigned to Arm(s): Intervention Patients & Providers, Intervention Patients, Control Providers | Intervention Type: BEHAVIORAL; Name: DECIDE-PC; Assigned to Arm(s): Intervention Providers
B: Arm Label: MOMCare intervention; Type: EXPERIMENTAL; Interventions: Behavioral: MOMCare | Arm Label: Care Plus; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: MOMCare; Assigned to Arm(s): MOMCare intervention
C: Arm Label: Standard Resource Sheet; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Standard Resource Sheet | Arm Label: Electronic Patient Decision Aid; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Electronic Patient Decision Aid, Behavioral: Standard Resource Sheet | Intervention Type: BEHAVIORAL; Name: Electronic Patient Decision Aid; Assigned to Arm(s): Electronic Patient Decision Aid | Intervention Type: BEHAVIORAL; Name: Standard Resource Sheet; Assigned to Arm(s): Electronic Patient Decision Aid, Standard Resource Sheet
D: Arm Label: Feedback Group; Type: EXPERIMENTAL; Interventions: Behavioral: Communication Feedback Form for Patients with Serious Illness | Arm Label: Comparison/Usual Care Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Communication Feedback Form for Patients with Serious Illness; Assigned to Arm(s): Feedback Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Prospective Cohort of Patient With Coronary Stents Undergoing Non Cardiac Surgery or Invasive Procedures.
Brief Summary: Non cardiac surgery in patients with coronary stents is complicated with cardiovascular and hemorrhagic events associated with perioperative management of antiplatelet agents. Several guidelines have outlined the importance of maintaining antiplatelet agents throughout surgical procedures to prevent cardiovascular complications. On the other hand, interruption of antiplatelet agents is still a usual standard to avoid surgical complications. We investigate the impact of perioperative antiplatelet drugs management on these complications, through a multicenter, prospective cohort (RECO stands for "Registre des patients porteurs d'Endoprothèses Coronaires, Opérés de chirurgie non cardiaque"), including all patients with coronary stents undergoing non cardiac surgery or invasive procedures. The aim of this study is primarily to measure the incidence of cardiovascular (including stent thrombosis) and hemorrhagic complications and to identify pre and postoperative risk factors associated with these complications.


Options:
A: N/A
B: N/A
C: Arm Label: Fludarabine+Cyclophosphamide+Rituximab (FCR); Type: EXPERIMENTAL; Interventions: Drug: Rituximab, Drug: Cyclophosphamide, Drug: Fludarabine Phosphate | Arm Label: Fludarabine+Cyclophosphamide (FC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Fludarabine Phosphate | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Fludarabine+Cyclophosphamide+Rituximab (FCR) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Fludarabine+Cyclophosphamide (FC), Fludarabine+Cyclophosphamide+Rituximab (FCR) | Intervention Type: DRUG; Name: Fludarabine Phosphate; Assigned to Arm(s): Fludarabine+Cyclophosphamide (FC), Fludarabine+Cyclophosphamide+Rituximab (FCR)
D: N/A

Answer: D